Arch Biopartners Inc.
ARCH.V is a Canadian-based company operating in the pharmaceuticals industry, primarily engaged in the development and commercialization of innovative therapies for rare diseases, with a focus on hematology and oncology.
Business. ARCH.V is a pharmaceutical company operating within the Healthcare sector. The firm is listed on the TSX Venture Exchange under the ticker symbol ARCH.V. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ARCH.V is a pharmaceutical company operating within the Healthcare sector. The firm is listed on the TSX Venture Exchange under the ticker symbol ARCH.V. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available.
The company's capital structure is highly leveraged, with total liabilities of CAD 3.99 billion and total equity of CAD -3.88 billion, resulting in a negative debt-to-equity ratio of -0.73. Liquidity is critically constrained, as evidenced by a current ratio of 0.03 and cash and equivalents of only CAD 2,100. The negative operating cash flow of CAD -1.58 billion further exacerbates the liquidity risk.
Profitability is severely challenged, with a net loss of CAD -1.55 billion and an operating loss of CAD -1.50 billion in the latest reporting period. Return on assets is negative at -14.85%, and return on equity is a marginal 0.4%, indicating poor capital efficiency and asset utilization. These metrics fall well below the industry median for pharmaceutical companies, which typically exhibit positive ROIC and ROE figures.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to market-specific risks, particularly in the Canadian healthcare market where the company is headquartered.
Growth trajectory is negative, with no disclosed revenue growth in the latest period and a net loss that has widened compared to prior periods. The outlook for the current fiscal year is not provided, but the company's financial position suggests a high likelihood of continued losses and potential liquidity constraints in the near term.
Risk factors include a severe liquidity crunch, with negative net cash after subtracting total debt, and a high probability of continued operating losses. The dilution risk is currently low, but the company's negative equity position and high debt load could necessitate future equity issuances, which would increase dilution pressure.
Recent events include the filing of a 2023 annual report, which disclosed ongoing challenges in clinical development and regulatory approval timelines for key pipeline assets. No recent earnings call transcripts or material regulatory changes were identified in the available data.
- The company is in a severe liquidity crisis with a current ratio of 0.03 and negative net cash.
- Operating and net losses have widened, with a net loss of CAD -1.55 billion in the latest period.
- The company's capital structure is highly leveraged, with total liabilities exceeding total assets by CAD 3.88 billion.
- Revenue is concentrated in a single business segment, with no geographic diversification disclosed.
- The outlook for profitability and liquidity is highly uncertain, with no material growth drivers identified in the latest data.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- ARCH.V Market data — financials · 2026-05-27
Ownership & reference
Leadership
- Richard MuruvePresident, Chief Executive Officer, Director